Physician profile
Fern Ellen Mayer
NPI 1386630085
$2,549.82
in general payments reported to CMS, 2019-2025
25 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.61 · 2021: $21.61 · 2022: $385 · 2023: $630 · 2024: $99.68 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.73 |
| Education | $162.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $314.48 | 2021-2025 | Opzelura |
| Genzyme Corporation | $281.01 | 2023-2025 | |
| Abbvie INC. | $269.82 | 2023-2025 | |
| Janssen Biotech, INC. | $222.29 | 2023-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $196.35 | 2022-2025 | Jublia, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $190.41 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $189.88 | 2020-2025 | Nemluvio |
| Leo Pharma INC. | $162.36 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $136.15 | 2022-2025 | |
| Lilly USA, LLC | $88.84 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $81.06 | 2022-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $61.78 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $45.32 | 2023-2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $38.47 | 2023-2025 | Zoryve |
| Almirall LLC | $33.40 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $32.54 | 2025 | Bimzelx |
| Journey Medical Corporation | $30.26 | 2022-2023 | |
| Organon LLC | $28.73 | 2025 | |
| Blueprint Medicines Corporation | $26.86 | 2023 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $23.61 | 2025 | Sotyktu |
| Amgen INC. | $22.15 | 2025 | Otezla |
| Lnhc, INC | $21.34 | 2025 | Zelsuvmi |
| Botanix Sb INC | $19.96 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $17.45 | 2022 | |
| Dermavant Sciences, INC. | $15.30 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fern Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.